United States Department of Defense
1400 Defense Pentagon, Room 1E757
38 articles with United States Department of Defense
SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®- In 2022
SIGA Technologies, Inc. today announced that the U.S. Department of Defense (DoD) awarded a new contract to SIGA for the procurement of up to $10.7 million of oral TPOXX.
GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens
GigaGen Inc. announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombinant human polyclonal antibody discovery platform against biological threats of interest to the DOD.
Codagenix Announces Award with the US Department of Defense for Development of Balanced, Tetravalent Dengue Vaccine
Codagenix Inc. today announced the Department of Defense has granted the company a $4.4 million award to progress development of CodaVax-DENV, its next-generation tetravalent dengue vaccine candidate.
Most money moves happened in Europe this week, including a government-backed award for Parkinson’s disease research and seed funding for an RNA platform.
Monday, Moderna told a Delaware federal court that it was immune from patent-infringement charges over the COVID-19 vaccine because it supplied the vaccine for a U.S. government effort.
Ventus Therapeutics Awarded Grant by the U.S. Department of Defense to Study the Role of cGAS in Lupus
Ventus Therapeutics, Inc. announced today that it has been awarded a Lupus Research Program Idea Award from the U.S. Department of Defense (DoD).
Partner Therapeutics Announces Contract with U.S. Department of Defense for Advanced Development of Leukine® to Treat Sulfur Mustard Gas (HD) Exposure
Partner Therapeutics, Inc. (PTx) today announced a milestone-based Other Transaction Agreement (OTA) with the United States Department of Defense (DoD) to fund development and regulatory activities to support an sBLA of Leukine.
Resilience Subsidiary Ology Bioservices Awarded Contract Worth Up To $250 Million from U.S. Department of Defense for Botulinum Neurotoxin Treatment
National Resilience, Inc. today announced the U.S. Department of Defense (DOD) has awarded Ology Bioservices, Inc. (Ology), a wholly owned subsidiary of Resilience, a contract valued as much as $250 million for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxin.
Ischemix, Inc. Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)
Ischemix, Inc., a private company focused on developing therapeutics for serious medical conditions, announced that the US Department of Defense has made a $2.9 award to the Company to fund a Phase 1 study of CMX-2043, a novel compound for the treatment of acute TBI.
Ellume Announces $231.8 Million Agreement with the U.S. Government to Scale Up Production of COVID-19 Home Tests
The investment will support the establishment of Ellume’s first U.S. manufacturing facility, increasing Ellume’s global production capacity by 500,000+ tests per day once completed
Just - Evotec Biologics Expands Contract with the Department of Defense for Manufacturing of Monoclonal Antibodies
Evotec SE announced that the U.S. Department of Defense awarded its Seattle, Washington-based subsidiary, Just - Evotec Biologics, Inc., an agreement worth $28.6 million for the production of monoclonal antibodies for use in the development of a treatment and/or prophylaxis for COVID-19.
BIO 300 will be tested as a post-infection prophylactic to mitigate pulmonary inflammation leading to COVID-19 complications
Cue's Molecular, Point-of-Care COVID-19 Tests Now Available in 10 States Under Health and Human Services and Department of Defense Pilot Program
Cue Health Inc. announced that its molecular, point-of-care COVID-19 Tests are being distributed to five additional states, including Colorado, Minnesota, Pennsylvania, Rhode Island and Utah, as part of the joint $481 million program with the U.S. Department of Health and Human Services and the Department of Defense.
The U.S. Department of Defense awarded Moderna a contract worth $1,966,598,000 for an additional 100 million doses of its COVID-19 vaccine.
BioXcel Therapeutics Announces Grant by U.S. Department of Defense to Evaluate BXCL501 in Patients Suffering from PTSD
Grant will support clinical studies in patients with post-traumatic stress disorder related to alcohol and substance abuse
Humanigen Announces Cooperative Research and Development Agreement with the Department of Defense to Develop Lenzilumab for COVID-19
The Cooperative Research and Development Agreement (CRADA) with the Department of Defense (DoD) in support of Operation Warp Speed (OWS) aims to improve the availability of lenzilumab for patients with COVID-19 Humanigen’s development efforts complemented by full-scale, integrated team of OWS leading experts and U.S. Government decision makers dedicated to advancing lenzilumab ahead of a potential Emergency Use Authorization (EUA) submission
Department of Defense Awards Ology Bioservices Contract to Manufacture and Test Novel Live Attenuated Tularemia Vaccine Candidate
Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced today that the Department of Defense (DOD), through the Joint Science and Technology Office of the Defense Threat Reduction Agency (DTRA), has awarded the company with a contract to manufacture a novel live attenuated tularemia vaccine. The contract value is $6.3 million. The vaccine candidate ATI-1701
Partner Therapeutics Announces $35 Million Contract with U.S. Department of Defense for Advanced Development and Emergency Use of Leukine® (rhuGM-CSF) for COVID-19 Acute Hypoxemic Respiratory Failure (AHRF)
Funding will support two randomized, multi-center clinical trials in COVID-19 patients, expansion of manufacturing capacity and potential Emergency Use Authorization filing
DOD to Fund a Multi-Center Randomized Clinical Trial of COVID-19 Treatment With ExThera’s Seraph 100 Blood Filter
After encouraging preliminary results in the treatment of critically-ill COVID-19 patients at a military hospital in the United States and fourteen other hospitals in Europe, the Department of Defense has selected the Seraph®100 Microbind® Affinity Blood Filter (Seraph 100) as one of its main interventions in a pivotal, US-based randomized controlled trial. Financial support for the multi-center trial will be provided
“We are genuinely honored at the opportunity to protect our military personnel and their families who have devoted themselves to the needs of U.S. citizens and others worldwide,” said Stanley C. Erck, president and chief executive officer of Novavax.